FENC FENNEC PHARMACEUTICALS INC.

Nasdaq fennecpharma.com


$ 7.98 $ -0.02 (-0.25 %)    

Friday, 07-Nov-2025 15:59:54 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 7.98
$ 7.97
$ 7.00 x 3
$ 9.50 x 50
-- - --
$ 3.96 - $ 9.92
52,480
na
222.1M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 02-14-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 03-15-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-28-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-29-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-12-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-28-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 craig-hallum-maintains-buy-on-fennec-pharmaceuticals-raises-price-target-to-14

Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price targ...

 fennec-pharmaceuticals-q2-eps-011-misses-004-estimate-sales-965m-beat-952m-estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate...

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 craig-hallum-maintains-buy-on-fennec-pharmaceuticals-raises-price-target-to-13

Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price targ...

 fennec-pharmaceuticals-q1-eps-004-beats-009-estimate-sales-875m-beat-818m-estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate o...

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 nasdaq-sp-500-hit-6-month-lows-as-recession-fears-grow-whats-driving-markets-monday

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq ...

 fennec-pharmaceuticals-q4-2024-gaap-eps-006-up-from-010-yoy-sales-792m-down-from-973m-yoy

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.06) per share. This is a 40 percent increase over losses ...

Core News & Articles

Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that Norgine Pharmaceut...

 fennec-pharmaceuticals-announced-the-early-repayment-of-13m-of-its-approximately-32m-outstanding-convertible-debt-facility-with-petrichor-healthcare-capital-management

Pro forma for repayment, the convertible debt facility with Petrichor will be approximately $19 million and maintain a maturity...

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 fennec-pharmaceuticals-q3-eps-021-misses-010-estimate-sales-697m-miss-882m-estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate...

 hc-wainwright--co-maintains-buy-on-fennec-pharmaceuticals-lowers-price-target-to-13

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and lowers the ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION